December 14, 2023 | Daily JAM, Jubak Picks, MRNA |
Shares of Moderna (MRNA) closed up 925% today, December 14. A personalized vaccine developed by Merck and Moderna helped prevent the recurrence of severe skin cancer for three years, according to new results released today. Patients with severe melanomas who got the vaccine and Merck’s cancer drug Keytruda were 49% less likely to die or have their cancer return than those who got Keytruda alone. The news is especially important for Moderna.
October 29, 2019 | Daily JAM, Stock Alerts |
 Shares of Merck (MRK) closed up 3.50% today, October 29, after the company reported better than expected third quarter earnings. On a Non-GAAP basis earnings of $1.51 a share beat the Wall Street consensus by 27 cents a share. Revenue of $12.4 billion fell 6.7% year...
April 1, 2019 | Daily JAM, MRK, Stock Alerts |
Merck's cancer drug Keytruda continues to build global momentum. Today Merck (MRK) announced that China has approved Keytruda for first-line treatment of metastatic nonsquamous non-small cell lung cancer in combination with chemotherapy. The stock, which is a member...
May 1, 2018 | Daily JAM, MRK, Stock Alerts |
This morning before the New York markets opened Merck (MRK) reported earnings of $1.05 a share, ahead of the $1.00 a share forecast by Wall Street analysts. Earnings were up 19.3% from the first quarter of 2017. Revenue grew 6% to $10 billion. That narrowly missed the...